What is the recommended diagnostic workup and initial treatment for a suspected inflammatory demyelinating polyneuropathy such as chronic inflammatory demyelinating polyneuropathy?

Diagnostic Workup and Initial Treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

For suspected inflammatory demyelinating polyneuropathy such as CIDP, initiate treatment with intravenous immunoglobulin (IVIg) or corticosteroids as first-line therapy after confirming the diagnosis through clinical assessment, electrodiagnostic studies demonstrating demyelination, and exclusion of mimicking disorders. 1

Diagnostic Workup

Clinical Assessment

• Document the phenotype: Typical CIDP presents with symmetric proximal and distal weakness affecting both upper and lower limbs, sensory dysfunction, and diminished/absent reflexes 1, 2
• Identify variant forms: Multifocal CIDP, distal CIDP, pure motor CIDP, or pure sensory CIDP 1
• Screen for "red flags" that suggest alternative diagnoses: muscle atrophy, autonomic involvement (which is uncommon in CIDP), or disease progression faster than 8 weeks 3

Electrodiagnostic Studies (Essential)

Nerve conduction studies and EMG are mandatory to demonstrate peripheral nerve demyelination 4, 1:

• Look for motor conduction velocity slowing (ulnar nerve <35.7 m/s is highly suggestive) 3
• Document conduction block (ulnar motor conduction block has OR 13.37 for CIDP) 3
• Prolonged distal latencies and temporal dispersion 1
• The European Academy of Neurology/Peripheral Nerve Society 2021 criteria require electrophysiologic evidence of demyelination for diagnosis 1, 2

Laboratory Investigations

Perform comprehensive screening to exclude mimicking disorders 4:

• Complete blood count, comprehensive metabolic panel, erythrocyte sedimentation rate 4
• Blood glucose (diabetes is the most common mimic) 4
• Serum B12 with metabolites (methylmalonic acid and homocysteine) - B12 deficiency found in 2.2-8% of polyneuropathy cases 4
• Thyroid function tests 4
• Serum protein immunofixation electrophoresis (abnormal in ~9% of polyneuropathy cases) 4
• HIV testing 4

Additional Diagnostic Studies

Obtain neurology consultation early 4:

• MRI of spine with and without contrast to rule out compressive lesions and evaluate for nerve root enhancement/thickening 4
• Lumbar puncture: CSF typically shows elevated protein (often >45 mg/dL) and may show elevated white blood cells (though this differs from classic Guillain-Barré) 4
• Consider paraneoplastic antibody panel if atypical features present 4

Supportive Investigations to Consider

• Autonomic testing may be considered to document autonomic dysfunction, though autonomic involvement argues against typical CIDP 4
• Nerve biopsy is generally reserved for atypical presentations or suspected vasculitis/amyloidosis 4
• Skin biopsy for intraepidermal nerve fiber density may help in small fiber sensory polyneuropathy but has limited role in typical CIDP 4

Initial Treatment

First-Line Therapy (Choose One)

IVIg (Level A recommendation) or corticosteroids (Level C recommendation) 1, 5:

Intravenous Immunoglobulin:

• Dose: 2 g/kg total dose divided over 2-5 days (typically 0.4 g/kg/day for 5 days) 4, 1
• Preferred for pure motor CIDP 1, 6, 5
• Evaluate response at 2-4 weeks; if insufficient response, consider switching to corticosteroids or adding plasma exchange 1

Corticosteroids:

• Prednisone 1 mg/kg/day orally (maximum 60-80 mg/day in adults) 4
• Alternative: IV methylprednisolone 500-1000 mg/day for 3-5 days for severe presentations 4
• Taper over at least 4-6 weeks based on clinical response 4

Second-Line Therapy

If IVIg and corticosteroids are ineffective, initiate plasma exchange (Level A recommendation) 1, 6, 5:

• Typically 5 sessions over 2 weeks 4
• Note: Plasma exchange immediately after IVIg will remove immunoglobulin, so timing matters 4

Treatment Response Assessment

Objectify treatment response using validated measures 2:

• Document changes in muscle strength (Medical Research Council grading)
• Assess functional disability (I-RODS score, which averaged 62.1 in real-world cohorts) 7
• Evaluate at 3-6 months for maintenance therapy decisions 1
• Absence of objective improvement should prompt reconsideration of the CIDP diagnosis 2

Common Pitfalls to Avoid

Diagnostic Errors

• Misdiagnosis occurs in 37.2% of CIDP cases, with median diagnostic delay of 6 months 7
• The most common mimics include diabetic neuropathy, IgG4-nodopathies, POEMS syndrome, anti-MAG neuropathy, and Charcot-Marie-Tooth disease 3
• A probability calculator using clinical and electrophysiologic variables (available at https://news.mayocliniclabs.com/cidp-calculator/) can assist differentiation, with scores below 92% unlikely to represent CIDP 3

Treatment Considerations

• Avoid medications that can worsen neuromuscular transmission if myasthenia gravis is in the differential: β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, macrolides 4
• Monitor for concurrent myocarditis if elevated CPK or troponin (perform ECG and echocardiogram) 4
• Frequent neurologic checks and pulmonary function monitoring are essential for severe cases 4

Maintenance Therapy

For patients responding to initial treatment, maintenance therapy is recommended 1:

• IVIg, subcutaneous immunoglobulin, or corticosteroids 1
• If maintenance doses are high or response inadequate, consider combination therapy or adding immunosuppressants (azathioprine, methotrexate, mycophenolate) 1, 6
• Despite guideline-based treatment, 11% of patients report dissatisfaction with treatment outcomes and 12.2% with symptom control 7